Mereo BioPharma Group (HAM:MAH0) ROCE % : -81.18% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Mereo BioPharma Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Mereo BioPharma Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -81.18%.

Mereo BioPharma Group ROCE % Historical Data

The historical data trend for Mereo BioPharma Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group ROCE % Chart

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-69.23

-280.89

22.13

-39.33

-48.59

Mereo BioPharma Group Quarterly Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial												16.55	-75.46	-95.34	-78.80	-81.18

Mereo BioPharma Group ROCE % Calculation

Mereo BioPharma Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-24.866	/	( ( (73.078 - 23.01)	+	(60.98 - 8.699) )	/ 2 )
	=	-24.866	/	( (50.068	+	52.281)	/ 2 )
	=	-24.866	/	51.1745
	=	-48.59 %

Mereo BioPharma Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-51.076	/	( ( (93.877 - 20.324)	+	(60.98 - 8.699) )	/ 2 )
	=	-51.076	/	( ( 73.553	+	52.281 )	/ 2 )
	=	-51.076	/	62.917
	=	-81.18 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Mereo BioPharma Group (HAM:MAH0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Mereo BioPharma Group ROCE % Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (HAM:MAH0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (HAM:MAH0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MREO:USA 0A9G:UK MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (HAM:MAH0) Headlines

No Headlines